Chronic Antagonism of the Mineralocorticoid Receptor Ameliorates Hypertension and End Organ Damage in a Rodent Model of Salt-Sensitive Hypertension

References

• Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849–1865.
   PubMed Web of Science ®Google Scholar
• Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension. Nat Rev Endocrinol 2010;6:83–93.
   PubMed Web of Science ®Google Scholar
• Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007;113:267–278.
   PubMed Web of Science ®Google Scholar
• Bayorh MA, Mann G, Walton M, Eatman D. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats. Clin Exp Hypertens 2006;28:121–132.
   PubMed Web of Science ®Google Scholar
• Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791–1800.
   PubMed Web of Science ®Google Scholar
• Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004; 43:1252–1257.
   PubMed Web of Science ®Google Scholar
• Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006;47:1084–1093.
   PubMed Web of Science ®Google Scholar
• Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, Noma T, Kohno M, Nishiyama A, Nakano D. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. Am J Physiol Renal Physiol 2009;297:F802–F808.
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15: 709–716.
   PubMed Web of Science ®Google Scholar
• Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117–123.
   PubMed Web of Science ®Google Scholar
• White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021–1026.
   PubMed Web of Science ®Google Scholar
• Brandish PE, Forest TW, Chen H, Gatto NT, Molon-Noblot S, Zwierzynski I, Szczerba P, Adamson GE, Ma BK, Flores OA, Hershey JC. Eplerenone Decreases Inflammatory Foci in Spontaneously Hypertensive Rat Hearts With Minimal Effects on Blood Pressure. J Cardiovasc Pharmacol 2009;53:44–51.
   PubMed Web of Science ®Google Scholar
• Zhou X, Ono H, Ono Y, Frohlich ED. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004;24:242–249.
   PubMed Web of Science ®Google Scholar
• Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007;292:R946–R954.
   PubMed Web of Science ®Google Scholar
• Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006;47(4):656–664.
   PubMed Web of Science ®Google Scholar
• Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831–1838.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.
   PubMed Web of Science ®Google Scholar
• Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health, 2003.
   Google Scholar
• World Health Organization (WHO). World Health Report 2002: reducing risks, promoting healthy life. Geneva: WHO, 2002.
   Google Scholar
• Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996;27:481–490.
   PubMed Web of Science ®Google Scholar
• Luft FC. Molecular genetics of salt-sensitivity and hypertension. Drug Metab Dispos 2001;29:500–504.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Iturbe B, Vaziri ND. Salt-sensitive hypertension–update on novel findings. Nep Physiol Rev 2005;85:679–715.
   PubMedGoogle Scholar
• Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 2005;85:679–715.
   PubMed Web of Science ®Google Scholar
• Cowley AW Jr. The genetic dissection of essential hypertension. Nat Rev Genet 2006;7:829–840.
   PubMed Web of Science ®Google Scholar
• Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med 2008;86:729–734.
   PubMed Web of Science ®Google Scholar
• Roman RJ. Abnormal renal hemodynamics and pressure-natriuresis relationship in Dahl salt-sensitive rats. Am J Physiol 1986;251:F57–F65.
   PubMed Web of Science ®Google Scholar
• Liang M, Yuan B, Rute E, Greene AS, Olivier M, Cowley AW Jr. Insights into Dahl salt-sensitive hypertension revealed by temporal patterns of renal medullary gene expression. Physiol Genomics 2003;12:229–237.
   PubMed Web of Science ®Google Scholar
• Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 1997;96:2407–2413.
   PubMed Web of Science ®Google Scholar
• Meng S, Cason GW, Gannon AW, Racusen LC, Manning RD Jr. Oxidative stress in Dahl salt-sensitive hypertension. Hypertension 2003;41:1346–1352.
   PubMed Web of Science ®Google Scholar
• Gu JW, Tian N, Shparago M, Tan W, Bailey AP, Manning RD Jr. Renal NF-kappaB activation and TNF-alpha upregulation correlate with salt-sensitive hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 2006;291:R1817–R1824.
   PubMed Web of Science ®Google Scholar
• Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, Staedtler F, Mahl A, Grenet O, Roth DR, Wahl D, Legay F, Holder D, Erdos Z, Vlasakova K, Jin H, Yu Y, Muniappa N, Forest T, Clouse HK, Reynolds S, Bailey WJ, Thudium DT, Topper MJ, Skopek TR, Sina JF, Glaab WE, Vonderscher J, Maurer G, Chibout SD, Sistare FD, Gerhold DL. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 2010;28:486–494.
   PubMed Web of Science ®Google Scholar
• Crowley SD, Vasievich MP, Ruiz P, Gould SK, Parsons KK, Pazmino AK, Facemire C, Chen BJ, Kim HS, Tran TT, Pisetsky DS, Barisoni L, Prieto-Carrasquero MC, Jeansson M, Foster MH, Coffman TM. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009;119:943–953.
   PubMed Web of Science ®Google Scholar
• Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE; Subcommittee of Professional and Public Education of the American Heart Association. Recommendations for blood pressure measurement in humans and experimental manimals. Part 2: Blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension 2005;45:299–310.
   PubMed Web of Science ®Google Scholar
• Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007;116:268–275.
   PubMed Web of Science ®Google Scholar
• Huang BS, Van Vliet BN, Leenen FH. Increases in CSF [Na+] precede the increases in blood pressure in Dahl S rats and SHR on a high-salt diet. Am J Physiol Heart Circ Physiol 2004;287:H1160–H1166.
   PubMed Web of Science ®Google Scholar
• Gomez-Sanchez EP, Fort C, Thwaites D. Central mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rats. Am J Physiol Endocrinol Metab 1992;262:E96–E99.
   Google Scholar
• Brown NJ. Eplerenone: cardiovascular protection. Circulation 2003;107:2512–2518.
   PubMed Web of Science ®Google Scholar
• Sterzel RB, Luft FC, Gao Y, Schnermann J, Briggs JP, Ganten D, Waldherr R, Schnabel E, Kriz W. Renal disease and the development of hypertension in salt-sensitive Dahl rats. Kidney Int 1988;33:1119–1129.
   PubMed Web of Science ®Google Scholar
• Dluhy RG, Williams GH. Aldosterone–villain or bystander? N Engl J Med 2004;351:8–10.
   PubMed Web of Science ®Google Scholar
• Bayorh MA, Ganafa AA, Emmett N, Socci RR, Eatman D, Fridie IL. Alterations in aldosterone and angiotensin II levels in salt-induced hypertension. Clin Exp Hypertens 2005;27:355–367.
   PubMed Web of Science ®Google Scholar
• Hilfenhaus M. Circadian rhythm of the renin-angiotensin-aldosterone system in the rat. Arch Toxicol 1976;36:305–316.
   PubMed Web of Science ®Google Scholar
• Gomez-Sanchez C, Holland OB, Higgins JR, Kem DC, Kaplan NM. Circadian rhythms of serum renin activity and serum corticosterone, prolactin, and aldosterone concentrations in the male rat on normal and low-sodium diets. Endocrinology 1976;99: 567–572.
   PubMed Web of Science ®Google Scholar
• Ryoyu T, Isamu M, Ikeda Masatoshi I, Hideo K, Yoshiyu T, Shuichiro Y, Morise Toshio M, Hiroaki T. Circadian rhythm of plasma aldosterone and time dependent alterations of aldosterone regulators. J Steroid Biochemistry 1984;20:s321–323.
   PubMedGoogle Scholar
• Hurwitz S, Cohen RJ, Williams GH. Diurnal variation of aldosterone and plasma renin activity: timing relation to melatonin and cortisol and consistency after prolonged bed rest. J Appl Physiol 2004;96:1406–1414.
   PubMed Web of Science ®Google Scholar
• Weir, M, Rolfe, M: Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010;5:531–548.
   PubMed Web of Science ®Google Scholar